Sparsha Pharma International

Production

State-of-the-art Manufacturing Infrastructure

Sparsha Pharma International is equipped with state-of-the-art, purpose-built manufacturing systems with cutting-edge Japanese technology, ensuring precision, reliability, and superior product performance. Our infrastructure supports the production of a wide range of transdermal delivery systems, offering scalability and flexibility to meet dynamic global market demands. The facility encompasses over 40,000 square feet of GMP-compliant production space, thoughtfully designed with provisions for future expansion. Of this, 14,000 square feet is dedicated to active production, featuring sophisticated machinery for the development of matrix transdermal patch technologies.

Integrated into our operations is a 3,000 square foot Quality Control (QC) laboratory, equipped with state-of-the-art analytical instruments and systems capable of performing rigorous testing on both pharmaceutical raw materials and finished transdermal products. Our QC protocols align with national (I.P.) and international pharmacopeial standards, ensuring each product meets stringent quality, safety, and efficacy criteria.

Currently, the facility boasts a robust manufacturing capacity, capable of producing 10 to 15 million transdermal patches per shift. This high-throughput capability, combined with our technological expertise and quality-driven approach, makes Sparsha Pharma a trusted partner for commercial manufacturing, product lifecycle management, and international supply chain integration.

Founded in 2008, our journey is built on over a decade and a half of specialised experience exclusively in transdermal systems. This deep expertise fuels our continuous innovation and allows us to tackle complex drug delivery challenges for our global partners. Our forward-looking strategy is firmly centred on expanding our international footprint and pioneering the next generation of advanced transdermal therapeutics.

Currently, the facility boasts a robust manufacturing capacity, capable of producing over 5 million patches annually to both domestic and international markets, supported by a manufacturing capacity exceeding 10 million patches per annum. This high-throughput capability, combined with our technological expertise and quality-driven approach, makes Sparsha Pharma a trusted partner for commercial manufacturing, product lifecycle management, and international supply chain integration.

Production Plant

Survey No. 354, Muppireddypally Village, Manoharabad (Mandal), Medak District - 502336 Telangana State, India.

Quality Policy

Our mission at Sparsha Pharma is to develop clinically effective, innovative and affordable Transdermal therapeutic products to improve the quality of life of patients in need of such therapies.

Sparsha Pharma products are to meet international standards of quality.

We, as a Team, dedicate ourselves to achieve this objective by maintaining quality every stage and by complying with all current regulatory requirements.

Unique Specifications

With a cumulative experience of over 30 years among our R&D professionals and more than 16 years of specialised expertise in matrix technology development, the R&D department at Sparsha Pharma has been instrumental in the development and commercialisation of advanced matrix transdermal patches since its inception, establishing Sparsha Pharma as the only Indian company with a strong and sustainable presence in the domestic and global transdermal technology market. Our proven track record includes the annual supply of over 5 million patches to both domestic and international markets, supported by a manufacturing capacity exceeding 10 million patches per annum, firmly positioning us as a leader in this niche transdermal segment.

Adhesion is a critical factor in transdermal drug delivery, directly influencing the efficacy and reliability of the therapy. Ensuring consistent adhesion performance in topical and humid climates like India is a key challenge for most manufacturers. At Sparsha Pharma, the adhesive quality of all our transdermal patches are superior and clinically proven, consistently outperforming other alternatives available in the market — a testament to our commitment to quality, innovation, and patient comfort.

Our Key Therapy Areas

Pain Management
CNS Disorder
Respiratory
Nicotine Replacement Therapy
Cosmetic Microneedle Patches (Hyaluronic Acid Patches)

Fentanyl Transdermal Patch (Fen-Touch/ Fen-Spar)

Fentanyl Transdermal Patches is indicated in the management of chronic intractable...

Diclofenac Transdermal patch (D-Touch)

Diclofenac Diethylamine B.P. 100 mg Transdermal Patch, for the relief of pain and inflammation...

Rivastigmine Transdermal Patch (RivaSpar)

Rivastigmine Transdermal Patches has just been launched in December 2012 for Alzheimer’s...

Buprenorphine Transdermal Patch (Bue Touch/ BueSpar)

Buprenorphine Transdermal Patches indicated in the management of moderate...

Lidocaine Patch 5% (Lido-Touch)

The Lidocaine patch 5% exhibit efficacy to treat pain related to post-herpetic neuralgia and is effective...

Nicotine Transdermal Patch (Nico-Touch)

NicoTouch patch is designed to help people quit smoking using the principle of nicotine...

Tulobuterol Transdermal Patch (Tulo-Touch)

Tulobuterol transdermal patch is a square system consisting of a release liner, drug in adhesive...

Hyaluronic Acid Patches (Hylo-Touch)

HyloTouch is powered by softtip hydrogel technology developed by Sparsha Pharma. Our patches use a smart transdermal delivery system that allows active ingredients to penetrate the skin deeply, delivering moisture and anti-aging benefits exactly where they're needed most.

Cosmetic Microneedle Patches

Cosmetic Microneedle Patches employ painless, tiny needles that disintegrate over time to treat the skin. The needles typically consist...